Kinnate Biopharma
Latest round
- Series C
Last raised
- Jul 2020
Total raised
- $163M
Investors
- 14
About Kinnate Biopharma
Based in California, US, and founded in 2018 by CEO Nima Farzan, Kinnate Biopharma, Inc. operates as a clinical-stage precision oncology company providing cancer treatments. In February 2024, XOMA Corporation agreed to acquire Kinnate Biopharma, Inc. Kinnate Biopharma, Inc. developed a pipeline of small molecule drug candidates through its Kinnate Discovery Engine. It offers two main clinical programs targeting solid tumors with RAF, NRAS, and FGFR-driven alterations. The company's lead product candidates include exarafenib, an investigational pan-RAF inhibitor for cancers with BRAF and NRAS mutations, and KIN-3248, an investigational FGFR inhibitor targeting cancers with FGFR2 and FGFR3 alterations. In addition, the firm provides early-stage programs including c-MET inhibitor designed to target resistant variants and a brain-penetrant CDK4 selective inhibitor program.
Who invested in Kinnate Biopharma
14 investors across 2 rounds
See all investors in Kinnate Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Kinnate Biopharma
Who invested in Kinnate Biopharma?
Kinnate Biopharma has 14 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kinnate Biopharma raised?
Kinnate Biopharma has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Kinnate Biopharma last raise money?
Kinnate Biopharma's most recent round on record is a Series C, in Jul 2020.
What does Kinnate Biopharma do?
Based in California, US, and founded in 2018 by CEO Nima Farzan, Kinnate Biopharma, Inc.
Where is Kinnate Biopharma headquartered?
Kinnate Biopharma is headquartered in San Diego, US.
Which VCs invest in companies like Kinnate Biopharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Kinnate Biopharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Kinnate Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.